Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 3Phase 2 1

Status

Unknown 6Recruiting 6Not yet recruiting 3Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Conditions

Neoplasms 87Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 73Recurrence 64Colorectal Neoplasms 63Pancreatic Neoplasms 60Melanoma 58Advanced Solid Tumor 57Carcinoma, Hepatocellular 56Multiple Myeloma 55Lymphoma 53Leukemia, Myeloid, Acute 53Advanced Solid Tumors 53Neoplasm Metastasis 50Stomach Neoplasms 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Lymphoma, B-Cell 40Solid Tumor 39Ovarian Neoplasms 38Lymphoma, Non-Hodgkin 38Lung Neoplasms 36Glioblastoma 35Prostatic Neoplasms 34Leukemia 28Head and Neck Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 26Uterine Cervical Neoplasms 25Burkitt Lymphoma 24Esophageal Neoplasms 23Urinary Bladder Neoplasms 20

Interventions

SHR-1701 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Unknown × Advanced Malignant Tumors × Clear all
NCT05193721 2024-03-20

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1 Unknown
25 enrolled

Advanced Malignant Tumors

NCT05728541 2023-02-17

Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 1 Unknown
367 enrolled

Advanced Malignant Tumors

NCT04708210 2022-10-12

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Unknown
256 enrolled

Advanced Malignant Tumors

NCT05198817 2022-06-28

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1 Unknown
240 enrolled

Advanced Malignant Tumors

NCT05110807 2022-02-14

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown
38 enrolled

Advanced Malignant Tumors

NCT04128085 2019-12-16

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown
30 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡